ALK's strategic partner Torii in final stage of clinical development for Japanese cedar allergy

2 September 2014

Japanese drugmaker Torii Pharmaceutical has begun a Phase II/III development program with Denmark-based allergy specialist ALK Abello (ALKB: DC) for a new allergy immunotherapy tablet to treat Japanese cedar tree pollen allergy.

Torii, a strategic partner of ALK, has advanced the clinical development program for the sublingual immunotherapy tablet (SLIT-tablet) and started trials in Japan. The study is expected to include around 1,000 subjects and has been designed to test the safety and efficacy of the SLIT-tablet in Japanese cedar tree pollen-induced allergic rhinitis.

Torii is also finalizing the development of ALK’s house dust mite SLIT-tablet, and filing with Japanese regulatory authorities is expected within six months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK